| Name | Title | Contact Details |
|---|
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.
Molecular Pharmacology Limited (USA) is a West Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations.
Access Bio Inc is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Townsend’s Louisiana treatment centers, we care for addiction as a single disease that is typically self-treated with alcohol, drugs, gambling, sex, compulsive overeating, and other substances.